Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 20, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - January 20, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

1/20/17 - "Process for Purification and Isolation of Estrogens" in Patent Application Approval Process (USPTO 20160375378)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Akula, Chandrashaker; Lomans, John; Tummidi, Madhukiran; Tatake, Prashant Anil, filed on September 12, 2016, was made available online on January 5, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent appl
1/20/17 - $112.62 Billion Precision Medicine Market Analysis & Trends 2016 - Therapeutics & Applications Forecasts to 2025 [Egypt Independent]
-Research and Markets has announced the addition of the "Precision Medicine Market Analysis& Trend- Therapeutics, Application- Forecast to 2025" report to their offering. Some of the prominent trends that the market is witnessing include Next-generation monoclonal antibody-based platforms are gaining momentum in Precision Medicine, New IT technolog
1/20/17 - $420 Million Global Platelet Rich Plasma Market: Trend Analysis & Forecast to 2022
Dublin- Research and Markets has announced the addition of the "Global Platelet Rich Plasma Market: Trend Analysis and Forecast to 2022" report to their offering. The global platelet rich plasma market is projected to grow with a CAGR between 9.6% and 12% during 2016-2022 and reach USD 420 million by 2022.. North America is accounted as the largest
1/20/17 - $420 Million Global Platelet Rich Plasma Market: Trend Analysis & Forecast to 2022 - Research and Markets
Research and Markets has announced the addition of the "Global Platelet Rich Plasma Market: Trend Analysis and Forecast to 2022" report to their offering. The global platelet rich plasma market is projected to grow with a CAGR between 9.6% and 12% during 2016-2022 and reach USD 420 million by 2022.. North America is accounted as the largest growing
1/20/17 - $95.59 Billion Transdermal Drug Delivery Market Analysis & Trends - Technology, Application - Forecast to 2025
Research and Markets has announced the addition of the "Transdermal Drug Delivery Market Analysis& Trends- Technology, Application- Forecast to 2025" report to their offering. The Global Transdermal Drug Delivery Market is poised to grow at a CAGR of around 11.6% over the next decade to reach approximately $95.57 billion by 2025.. Depending on th
1/20/17 - Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B [Sudan Tribune]
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European Medicines Agency Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeonas gene therapy program ABO-101 for children impacted by Sanfilippo...
1/20/17 - Abzena Shares Jump On ThioBridge Licensing Agreement In US
LONDON- Abzena PLC on Friday said it signed a licensing agreement with an undisclosed San Diego- based pharmaceutical company for its ThioBridge antibody drug conjugate linker technology. Shares in Abzena were up73% at 61.90 pence Friday following the announcement, the best performer on AIM. The life sciences group said it had entered into a master
1/20/17 - Actinium Announces Participation in Three Upcoming Hematology Events
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company will be attending three upcoming events focused on hematology. These events are expected to draw physicians from surrounding areas that refer patients to clinical...
1/20/17 - Acute Market Reports: Global Digestive Health Supplements Market 2016 to 2021 Size, Share, Trends and Forecasts: Acute Market Reports
Global Digestive Health Supplements Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Digestive Health Supplements industry, focusing on the main regions and the main countries. The report firstly introduced the Digestive Health Supplements basics: definitions, classifications,...
1/20/17 - Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA [Tehran Times (Iran)]
-Adamis Pharmaceuticals Corporation today announced that the U.S. Food and Drug Administration has accepted for review the Companys New Drug Application for its Epinephrine Pre-filled Syringe product candidate for the emergency treatment of anaphylaxis. Filed on December 15, 2016, the resubmission was intended to address the issues raised by the FD
1/20/17 - Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the results of additional data analyses related to cognitive function from its 12- week, randomized, double-blind, placebo-controlled Phase IIb clinical trial of MIN-101 as...
1/20/17 - Adicet Bio Appoints Anne Altmeyer as Chief Business Officer
By a News Reporter-Staff News Editor at Drug Week- Adicet Bio, Inc., a biopharmaceutical company focused on the development of next-generation cell immunotherapies, announced that it has appointed Anne Altmeyer Ph.D., M.B.A, M.P.H. as its Chief Business Officer. Dr. Altmeyer joined Adicet from Baxalta where she served as Vice President, Negotiati
1/20/17 - ADMP Waiting To See If 3rd Time Is Charm, FDA Nod For SGYP, Be All Ears For OTIC
SAINT HELIER- AbbVie's blockbuster blood cancer drug Imbruvica has been approved by the FDA for yet another indication- this time, for the treatment of patients with relapsed/refractory marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy. Adamis Pharmaceuticals Corp.' s resubmitted New Dr
1/20/17 - Advanced Drug Delivery Technology, Route Of Administration, End User Market Analysis & Trends 2016-2025: Increasing Demand for Generic Drugs and Biosimilars
Research and Markets has announced the addition of the "Advanced Drug Delivery Market Analysis& Trends- Technology, Route Of Administration, End User- Forecast to 2025" report to their offering. The Global Advanced Drug Delivery Market is poised to grow at a CAGR of around 7.8% over the next decade to reach approximately $330.70 billion by 2025..
1/20/17 - Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
By a News Reporter-Staff News Editor at Drug Week Gilead Sciences, Inc. announced that Alessandro Riva, MD, will join the company as Senior Vice President, Hematology and Oncology Therapeutic Area Head. Dr. Riva joins Gilead from Novartis Oncology, where he served as Head, Global Oncology Development. Prior to joining Novartis, Dr. Riva co-founde
1/20/17 - Alkermes' Corporate Presentation to be Webcast at the 35th Annual J.P. Morgan Healthcare Conference
By a News Reporter-Staff News Editor at Drug Week Alkermes plc announced that its corporate presentation will be webcast live at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2017 at 10:30 a.m. PT from the Westin St. Francis Hotel in San Francisco. Alkermes plc is a fully integrated, global biopharmaceutical company devel
1/20/17 - Alnylam to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference
By a News Reporter-Staff News Editor at Health& Medicine Week Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 9:00 am PT at The Westin St. In addition, the company will webcast the Q&A
1/20/17 - Amplitude Surgical Announces That is Has Been Granted Approval to Market Its Anatomic Total Knee Prosthesis in the United States
Amplitude Surgical, a leading French player on the global surgical technology market for lower-limb orthopedics, today announces that it has received 510 regulatory clearance from the US Food and Drug Administration for its Anatomic implant, addressing degenerative knee disorders. Olivier Jallabert, Chairman and CEO of Amplitude Surgical, says:
1/20/17 - Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017 [FARS News Agency]
-Anavex Life Sciences Corp. and the International Rett Syndrome Foundation, doing business as Rettsyndrome.org today announced that Rettsyndrome.org has committed a financial grant of a minimum of $0.6 million to cover the majority of a planned U.S. multicenter Phase 2 clinical trial of ANAVEX 2-73 for the treatment of Rett syndrome.
1/20/17 - ARMO BioSciences Presents New Phase 1b Clinical Data for AM0010 in Advanced Pancreatic Cancer Patients at 2017 Gastrointestinal Cancers Symposium
ARMO BioSciences, Inc., a late-stage immuno-oncology company, presented new Phase 1 b clinical data on the Company's lead investigational immuno-oncology drug AM0010 at the 2017 Gastrointestinal Cancers Symposium, co-sponsored by the American Society of Clinical Oncology, taking place January 19-21, 2017 in San Francisco, CA.. "AM0010 induces th
1/20/17 - Array Biopharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Dec. 29, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on December 29, 2016. The SEC file number is 0001562180-16-003916.. A U.S. Securities and Exchange Commission filing is a formal
1/20/17 - Aurobindo Receives FDA Approval for Ziprasidone HCl Capsules, 20 mg, 40 mg, 60 mg and 80 mg
Release date- 19012017- East Windsor, N.J.- Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Ziprasidone HCl Capsules, 20 mg, 40 mg, 60 mg and 80 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited's Ziprasidone HCl Capsules, 20 mg, 40 mg, 60 mg and 80 mg to be bioequivalent
1/20/17 - Aurora Biopharma, Inc. Files SEC Form D, Notice of Exempt Offering of Securities (Dec. 29, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Aurora Biopharma, Inc. was posted on December 29, 2016. The SEC file number is 0001691940-16-000002.. A U.S. Securities and Exchange Commission filing is a form
1/20/17 - Baxter Black: A journey to the FDA
But I can now claim I have seen the FDA in the Land of Acronyms, Washington, D.C., and survived. In my case, it was the FDA, CVM Food and Drug Administration Center for Veterinary Medicine. The mental picture I had before my visit was akin to the Supreme Court or a court martial a line of wizened, beady-eyed scowling geezers wearing robes and wigs
1/20/17 - Bioreactors Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 20162024
The global bioreactor market is segmented on the basis of scale range, usage, end-user, control, materials, suppliers, and region.Sarasota, FL 01/20/2017 Global Bioreactors Market: Overview. Bioreactor or fermenter is requisite equipment required for bioprocessing. Bioreactors are specifically constructed systems or vessels that can support a
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415